AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer

NCT06938503 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

48

Enrollment

OTHER

Sponsor class

Conditions

Pancreatic Cancer, Adult

Interventions

DRUG: AG regimen
DRUG: Nimotuzumab

Sponsor

Tianjin Medical University Cancer Institute and Hospital